Engdahl E, et al. Serological response against HHV-6A is associated with increased risk for multiple sclerosis. Abstract 222. ECTRIMS 2019, 11-13 sept 2019, Stockholm, Zweden.
Europese goedkeuring ocrelizumab
jan 2018 | Multipele Sclerose
jan 2024 | Neuro-vasculair
dec 2023 | Bewegingsstoornissen